B. Braun CeGaT to Present Scientific Findings During an

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
B. Braun CeGaT to Present Scientific Findings During an Exhibitor Presentation and Poster Session at the 2015 ARVO Annual Meeting; Will Highlight the Comprehensive Genomic Testing Services and Major Milestone of 1,000 Patient Samples Tested for Eye Diseases

BETHLEHEM, Pa., April 29, 2015 (GLOBE NEWSWIRE) -- Braun CeGaT, a molecular diagnostics service provider with extensive experience in the area of hereditary eye diseases, will be exhibiting at the 2015 ARVO Annual Meeting held May 3-7 in Denver, Colorado. The Pennsylvania-based company will highlight a catalog of next generation sequencing-based tests that are designed to identify the specific molecular cause of various hereditary forms of eye diseases and will present results of its scientific collaboration with the Eye Clinics of Tuebingen, Germany during an exhibitor presentation on Sunday May 3rd.

The latest update to our diagnostic services for hereditary eye disease includes 21 unique multi-gene panels and covers more than 320 genes known to be associated with retinal and related disorders including, among others, Usher syndrome, retinitis pigmentosa, achromatopsia, and Leber congenital amaurosis. The genes in these panels are sequenced at a very high coverage (800-1000x on average) to increase the probability of finding the causative variant in a patient’s DNA. B. Braun CeGaT has now analyzed over 1,000 patients for eye diseases, giving the company advanced knowledge and expertise in the genetic causes of these diseases. In addition to eye diseases, our growing repository of genetic information also includes data from more than 10,000 patient samples tested in various other disease areas such as epilepsy, oncology, cardiology, neuromuscular disorders, neurodegenerative disorders and metabolic disorders. The complete testing process is performed in-house – from DNA preparation and sequencing to the interpretation of results and issuing of a medical report.

CeGaT’s collaboration partner, Dr. Susanne Kohl from the Centre for Ophthalmology, University of Tuebingen (Germany), will speak during an exhibitor presentation about the scientific discoveries made possibly by using the testing services performed by CeGaT. Additionally, Dr. Nicola Gloeckle, team leader of Panel Diagnostics for Eye Disease at CeGaT, will present a poster detailing the lessons learned from the genetic analysis of more than 900 retinitis pigmentosa patients. Dr. Gloeckle will also be available at our booth for questions.

Exhibitor Presentation

Topic: Extensive Genetic Diagnostic Panels in Clinical Applications

Date/Time: Sunday May 3, 10:30am – 11:00am

Location: Presentation Area in Exhibit Hall, ARVO Annual Meeting (Colorado Convention Center, Denver, CO)

Poster Session

Topic: Unusual genetic findings in 900 patients clinically diagnosed with hereditary retinal dystrophies.

Date/Time: Sunday May 3, 3:15pm – 5:00pm

Location: Poster Board Area in Exhibit Hall (Posterboard # D0221, Abstract # 1244), ARVO Annual Meeting (Colorado Convention Center, Denver, CO)

Visit Booth #1712 during the 2015 ARVO Annual Meeting to learn more about the genetics of eye diseases and B. Braun CeGaT’s diagnostic and research services.

About B. Braun CeGaT, LLC

Braun CeGaT, established in 2014, is the result of a partnership between B. Braun, a leading provider of medical products and services, and the Center for Genomics and Transcriptomics (CeGaT), a Germany-based molecular diagnostic laboratory. The company, which shares its headquarters with B. Braun in Bethlehem, Pennsylvania, was formed to serve the US sequencing and diagnostics market by offering innovative molecular diagnostic services developed by CeGaT to US-based healthcare providers.

CeGaT has created and pioneered diagnostic services for a wide range of disorders including cancer, epilepsy, neuromuscular disease, neurodegenerative disease, eye/vision-related disease, and more. CeGaT’s approach utilizes recent advancements in next generation sequencing technology, allowing for the simultaneous analysis of all genes associated with a particular disease. The information revealed by these tests can be used to identify the underlying cause of the disease in an individual patient and to help guide the course of treatment based on the patient’s unique genetic profile.

Dawn Brooke B. Braun CeGaT, LLC 824 Twelfth Avenue Bethlehem, PA 18018-3524 USA Email: dawn.brooke@bbrauncegat.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 392

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 255

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 253

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 204

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 203

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 200

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 281

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 166

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Developments at Metals Exploration's La India Project

Updated Category News Views 256

Promising Outcomes of La India Gold Project Metals Exploration PLC (AIM: MTL), known for its expertise in gold production, has shared encouraging initial estimates from its internal analysis concerning the La India gold project in Nicaragua. These findings highlight a notable advancement when compared to the previous Bankable Feasibility Study (BFS) undertaken by SRK...

Continue Reading
Palo Alto Networks Faces Downgrade Amid CyberArk Acquisition Risk

Updated Category News Views 369

Palo Alto Networks Faces Recent Downgrade Palo Alto Networks, Inc. (NASDAQ: PANW) experienced a significant dip in its stock value, falling over 5% recently. This decline came on the heels of concerns surrounding strategic risks associated with its acquisition of CyberArk Software Ltd. (NASDAQ: CYBR). Concerns Over Acquisition Integration The acquisition has sparked...

Continue Reading
Widescale Protests Erupt in Slovakia Over Gas Supply Politics

Updated Category News Views 193

Protests Against Slovakia's Pivot Towards Russia In recent days, thousands of demonstrators gathered in Bratislava, expressing their discontent with Prime Minister Robert Fico's policies towards Russia amid a gas dispute with Ukraine. The protests highlighted growing concerns over Slovakia's geopolitical alignments and the implications for the country's future in Europe....

Continue Reading
Engage with The Hackett Group's Q4 2024 Earnings Call Details

Updated Category News Views 204

Join The Hackett Group for an Insightful Earnings Call The Hackett Group, Inc. (NASDAQ: HCKT) is excited to announce its upcoming earnings conference call scheduled for February 18, 2025. This call follows the release of its fourth-quarter financial results for the period ending December 27, 2024, which will be made public after the market closes on that day. Conference...

Continue Reading
Tintina Mines Welcomes New Director Amid Leadership Changes

Updated Category News Views 81

Tintina Mines Announces Leadership Changes Tintina Mines Limited (TSXV: TTS) has recently undergone a leadership transition, announcing the resignation of Mr. Ricardo Landeta from his position as Director. His decision to resign is due to personal reasons, marking a significant change for the firm. Introduction of New Director In conjunction with Mr. Landeta's departure,...

Continue Reading